{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:11:03Z","timestamp":1794006663298,"version":"4.8.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01531-w","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T09:29:01Z","timestamp":1784280541000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neoadjuvant Imatinib Therapy in Rectal Gastrointestinal Stromal Tumors: A Comprehensive Narrative Review of Tumor Downsizing, Sphincter Preservation, Transanal Surgical Platforms, Functional Outcomes, and Survival"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9633-7999","authenticated-orcid":false,"given":"Naga Praneeth","family":"Raja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagapavani","family":"Kandagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"8","key":"1531_CR1","doi-asserted-by":"publisher","first-page":"e2428828","DOI":"10.1001\/jamanetworkopen.2024.28828","volume":"7","author":"CS Alvarez","year":"2024","unstructured":"Incidence and Survival Outcomes of Gastrointestinal Stromal Tumors, Alvarez CS, Piazuelo MB, Fleitas-Kanonnikoff T, et al. JAMA Netw Open. 2024;7(8):e2428828. . https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.28828","journal-title":"JAMA Netw Open"},{"key":"1531_CR2","unstructured":"Gastrointestinal Stromal Tumors. National Comprehensive Cancer Network. Updated 2026-01-13."},{"issue":"7","key":"1531_CR3","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/jso.26628","volume":"124","author":"W Yang","year":"2021","unstructured":"The effect of, Yang W, Liu Q, Lin G, et al. neoadjuvant imatinib therapy on outcome and survival in rectal gastrointestinal stromal tumors: A multiinstitutional study. J Surg Oncol. 2021;124(7):1128\u201335. . https:\/\/doi.org\/10.1002\/jso.26628","journal-title":"J Surg Oncol"},{"issue":"9","key":"1531_CR4","doi-asserted-by":"publisher","first-page":"0270887","DOI":"10.1371\/journal.pone.0270887","volume":"17","author":"C Cheong","year":"2022","unstructured":"Impact of Neoadjuvant Treatment on Rectal Gastrointestinal Stromal Tumors, Cheong C, Kang J, Min BS, et al. PLoS ONE. 2022;17(9):0270887. . https:\/\/doi.org\/10.1371\/journal.pone.0270887","journal-title":"PLoS ONE"},{"key":"1531_CR5","unstructured":"FDA Orange Book. FDA Orange Book."},{"issue":"1","key":"1531_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12876-025-04467-w","volume":"26","author":"JH Chen","year":"2025","unstructured":"Comparative Efficacy of Neoadjuvant Imatinib Therapy in Gastric Versus Rectal Gastrointestinal Stromal Tumors: A Two-Center Retrospective Cohort Study, Chen JH, Cai ZM, Yang ZR, et al. BMC Gastroenterol. 2025;26(1):8. . https:\/\/doi.org\/10.1186\/s12876-025-04467-w","journal-title":"BMC Gastroenterol"},{"issue":"7","key":"1531_CR7","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/wjs.12210","volume":"48","author":"TJR Lam","year":"2024","unstructured":"A Systematic Review and Meta-Analysis of Neoadjuvant Imatinib Use in Locally Advanced and Metastatic Gastrointestinal Stromal Tumors, Lam TJR, Udonwa SA, Masuda Y, et al. World J Surg. 2024;48(7):1681\u201391. . https:\/\/doi.org\/10.1002\/wjs.12210","journal-title":"World J Surg"},{"key":"1531_CR8","doi-asserted-by":"publisher","unstructured":"Multimodal Functional Imaging for Early Response Assessment in Patients With Gastrointestinal Stromal Tumor Treated With Tyrosine Kinase Inhibitors, Revheim ME, Hole KH, Mo T et al. Acta RadiologicaStockholm, Sweden (1987). 2022;63(8):995\u20131004. https:\/\/doi.org\/10.1177\/02841851211027389","DOI":"10.1177\/02841851211027389"},{"key":"1531_CR9","doi-asserted-by":"publisher","first-page":"950101","DOI":"10.3389\/fphar.2022.950101","volume":"13","author":"W Li","year":"2022","unstructured":"Efficacy and Safety of Neoadjuvant Imatinib Therapy for Patients With Locally Advanced Rectal Gastrointestinal Stromal Tumors: A Multi-Center Cohort Study, Li W, Li X, Yu K, et al. Front Pharmacol. 2022;13:950101. . https:\/\/doi.org\/10.3389\/fphar.2022.950101","journal-title":"Front Pharmacol"},{"issue":"2","key":"1531_CR10","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1200\/JCO.2026.44.2_suppl.839","volume":"44","author":"J Kim","year":"2026","unstructured":"Clinical outcomes of, Kim J, Kim H, Lee H, et al. resected gastrointestinal stromal tumors treated with 3 years of adjuvant imatinib in different genotypes. J Clin Oncol. 2026;44(2):839. . https:\/\/doi.org\/10.1200\/JCO.2026.44.2_suppl.839","journal-title":"J Clin Oncol"},{"issue":"8","key":"1531_CR11","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/jso.26664","volume":"124","author":"JY Ling","year":"2021","unstructured":"Comparison of outcomes, Ling JY, Ding MM, Yang ZF, et al. between neoadjuvant imatinib and upfront surgery in patients with localized rectal GIST: An inverse probability of treatment weighting analysis. J Surg Oncol. 2021;124(8):1442\u201350. . https:\/\/doi.org\/10.1002\/jso.26664","journal-title":"J Surg Oncol"},{"key":"1531_CR12","doi-asserted-by":"publisher","first-page":"966486","DOI":"10.3389\/fphar.2022.966486","volume":"13","author":"Z Liu","year":"2022","unstructured":"Comparison of Prognosis Between Neoadjuvant Imatinib and Upfront Surgery for GIST, Liu Z, Zhang Z, Sun J, et al. A Systematic Review and Meta-Analysis. Front Pharmacol. 2022;13:966486. . https:\/\/doi.org\/10.3389\/fphar.2022.966486","journal-title":"Front Pharmacol"},{"issue":"1","key":"1531_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ijc.33536","volume":"149","author":"KE Marqueen","year":"2021","unstructured":"Neoadjuvant Therapy for Gastrointestinal Stromal Tumors: A Propensity Score-Weighted Analysis, Marqueen KE, Moshier E, Buckstein M, Ang C. Int J Cancer. 2021;149(1):177\u201385. . https:\/\/doi.org\/10.1002\/ijc.33536","journal-title":"Int J Cancer"},{"issue":"5","key":"1531_CR14","doi-asserted-by":"publisher","first-page":"71912","DOI":"10.1002\/cam4.71912","volume":"15","author":"H Mohammad","year":"2026","unstructured":"Adjuvant Imatinib for Patients Resected for GIST: A Quality Assurance Study, Mohammad H, Rose HK, Rossen PB, Aggerholm Pedersen N. Cancer Med. 2026;15(5):71912. . https:\/\/doi.org\/10.1002\/cam4.71912","journal-title":"Cancer Med"},{"issue":"3","key":"1531_CR15","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2015.62.9170","volume":"34","author":"H Joensuu","year":"2016","unstructured":"Adjuvant Imatinib for High-Risk GI Stromal Tumor, Joensuu H, Eriksson M, Sundby Hall K, et al. Analysis of a Randomized Trial. J Clin Oncology: Official J Am Soc Clin Oncol. 2016;34(3):244\u201350. . https:\/\/doi.org\/10.1200\/JCO.2015.62.9170","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"17","key":"1531_CR16","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1158\/1078-0432.CCR-22-3980","volume":"29","author":"H Joensuu","year":"2023","unstructured":"KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated With Adjuvant Imatinib in a Randomized Trial, Joensuu H, Wardelmann E, Eriksson M, et al. Clin Cancer Research: Official J Am Association Cancer Res. 2023;29(17):3313\u20139. . https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3980","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"issue":"12","key":"1531_CR17","doi-asserted-by":"publisher","first-page":"184060","DOI":"10.1001\/jamaoncol.2018.4060","volume":"4","author":"CP Raut","year":"2018","unstructured":"Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor, Raut CP, Espat NJ, Maki RG, et al. The PERSIST-5 Clinical Trial. JAMA Oncol. 2018;4(12):184060. . https:\/\/doi.org\/10.1001\/jamaoncol.2018.4060","journal-title":"JAMA Oncol"},{"issue":"5","key":"1531_CR18","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/14737140.2021.1863149","volume":"21","author":"P von Whooley","year":"2021","unstructured":"Deciding on the Duration of Adjuvant Therapy in Gastrointestinal Stromal Tumor, Whooley P, Correa E, von Mehren M. Expert Rev Anticancer Ther. 2021;21(5):547\u201356. . https:\/\/doi.org\/10.1080\/14737140.2021.1863149","journal-title":"Expert Rev Anticancer Ther"},{"issue":"8","key":"1531_CR19","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S1470-2045(24)00259-6","volume":"25","author":"D Bertsimas","year":"2024","unstructured":"Interpretable Artificial Intelligence to Optimise Use of Imatinib After Resection in Patients With Localised Gastrointestinal Stromal Tumours, Bertsimas D, Margonis GA, Sujichantararat S, et al. An Observational Cohort Study. Lancet Oncol. 2024;25(8):1025\u201337. . https:\/\/doi.org\/10.1016\/S1470-2045(24)00259-6","journal-title":"Lancet Oncol"},{"key":"1531_CR20","doi-asserted-by":"publisher","unstructured":"Circulating Tumor DNA, Kelly CM, Bradic M, Saunds S, et al. Clin Cancer Research: Official J Am Association Cancer Res. 2025;763735. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-0145","DOI":"10.1158\/1078-0432.CCR-25-0145"},{"issue":"12","key":"1531_CR21","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1158\/1535-7163.MCT-21-0403","volume":"20","author":"G Johansson","year":"2021","unstructured":"Monitoring Circulating Tumor DNA During Surgical Treatment in Patients With Gastrointestinal Stromal Tumors, Johansson G, Berndsen M, Lindskog S, et al. Mol Cancer Ther. 2021;20(12):2568\u201376. . https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0403","journal-title":"Mol Cancer Ther"},{"issue":"16","key":"1531_CR22","doi-asserted-by":"publisher","first-page":"11522","DOI":"10.1200\/JCO.2025.43.16","volume":"43","author":"Z Gao","year":"2025","unstructured":"Personalized tumor-informed, Gao Z, Cheng B, Yang S, et al. circulating tumor DNA analysis in monitoring recurrence following resection of high-risk locally advanced stage gastrointestinal stromal tumor. J Clin Oncol. 2025;43(16):11522. . https:\/\/doi.org\/10.1200\/JCO.2025.43.16","journal-title":"J Clin Oncol"},{"issue":"1","key":"1531_CR23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12885-020-6597-x","volume":"20","author":"C Serrano","year":"2020","unstructured":"Clinical Value of Next Generation Sequencing of Plasma Cell-Free DNA in Gastrointestinal Stromal Tumors, Serrano C, Vivancos A, L\u00f3pez-Pousa A, et al. BMC Cancer. 2020;20(1):99. . https:\/\/doi.org\/10.1186\/s12885-020-6597-x","journal-title":"BMC Cancer"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01531-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01531-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01531-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T09:29:04Z","timestamp":1784280544000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01531-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1531"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01531-w","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"4 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"158"}}